To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.
Summary
HR9972, a bill to adjust Medicare payment for skin substitute products, was introduced and referred to two committees on 2026-07-27. It is in an early legislative stage with no cosponsors, and no specific funding or market-moving provisions are identified. No direct market impact is anticipated at this stage.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR9972 is in an early legislative stage with no cosponsors, indicating low momentum.
- 2.No specific funding amount is authorized or appropriated by this bill.
- 3.Market impact is negligible until the bill advances and specific payment adjustments are detailed.
Market Implications
No immediate market implications. The bill is too early-stage to affect any publicly traded company's revenue or competitive position. Investors should watch for committee action and the introduction of specific payment rate changes that could impact manufacturers of skin substitute products, such as $AORT (Artivion) or $BSX (Boston Scientific), but no causal chain can be established now.
Full Analysis
HR9972 was introduced on July 27, 2026, by Rep. Pete Sessions (R-TX-17) and referred to the House Committees on Energy and Commerce and Ways and Means. The bill aims to amend title XVIII of the Social Security Act to adjust payment for skin substitute products under Medicare. As an early-stage bill with no cosponsors and no further action history, it has minimal legislative momentum. The bill does not authorize or appropriate any specific funding amount; it proposes a payment adjustment mechanism that would require subsequent rulemaking by the Centers for Medicare & Medicaid Services (CMS) if enacted. The legislative path is lengthy: it must pass through both committees, the full House, the Senate, and be signed into law. Given the procedural status and lack of detail on the specific payment adjustment, no publicly traded companies can be reliably identified as beneficiaries or losers at this stage. The bill's impact on the healthcare sector, specifically wound care and skin substitute manufacturers, is uncertain until committee markup reveals the scope of payment changes.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend title XVIII of the Social Security Act to provide for payment for services of radiologist assistants under the Medicare program, and for other purposes.
To amend title XVIII of the Social Security Act to expand access to psychological and behavioral services.
To amend title XVIII of the Social Security Act to provide for coverage of dental services under the Medicare program.
MULTIPLE RECIPIENTS: $4.9B Department of Health and Human Services Federal Award
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →